Structural and functional brain correlates of treatment-resistant depression: A systematic review of magnetic resonance imaging studies.

J Affect DisordMay 5, 2026 (epub)
Clinical ResearchPsychiatry

Lauren E Carter, Emily Lowery, Mitul A Mehta et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined structural and functional brain changes in treatment-resistant depression (TRD) compared to non-treatment-resistant major depressive disorder (MDD). Analyzing 27 studies, the review found that TRD patients exhibited reduced hippocampal volume and altered functional connectivity in brain regions including the frontal and temporal lobes. The findings highlight the need for standardized methodologies in future research.

Key findings

  • TRD patients showed reduced hippocampal volume compared to non-TRD MDD.
  • Altered functional connectivity was observed in the frontal, temporal, and parietal lobes in TRD.
  • Inconsistencies in white matter volume and integrity were noted across studies.

Why it matters

Understanding the brain correlates of treatment-resistant depression can inform clinicians about the underlying neurobiological mechanisms, potentially guiding more effective treatment strategies for this challenging patient population.

Source

PubMed · PMID 42097177

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.